Document Detail

Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma.
MedLine Citation:
PMID:  22591745     Owner:  NLM     Status:  Publisher    
OBJECTIVES: To evaluate the risk factors and prognosis of muscle-invasive bladder cancer (MIBC) developing after nephroureterectomy for upper urinary tract urothelial cell carcinoma (UUT-UC). MATERIALS AND METHODS: We reviewed the medical records of 422 patients who underwent nephroureterectomy for UUT-UC between 1990 and 2010, and identified 173 (40.9%) with intravesical recurrence and 28 (6.6%) with MIBC. We evaluated the clinicopathologic features, risk factors, and cancer-specific survival (CSS) using the Kaplan-Meier method and the Cox proportional hazards regression models. RESULTS: The median intervals from nephroureterectomy to intravesical recurrence and the development of MIBC were 8 and 17 months, respectively. On multivariate analysis, the pathologic stage (≥pT3 vs. Ta/T1, HR 5.03, P = 0.001) and ureteral tumor location (HR 2.79, P = 0.011) were independent risk factors for the development of MIBC, whereas a history of previous or concomitant bladder tumor was the only significant risk factor for intravesical recurrence. The probability of developing MIBC 5 years after nephroureterectomy was 12.6% in patients with 1 risk factor and 20.6% in patients with both risk factors. Patients with MIBC had significantly worse CSS than those without MIBC (P = 0.004), whereas CSS rates were similar in patients with and without intravesical recurrence (P = 0.593). However, stratification analysis for matching pathology revealed that CSS rates were not significantly different in patients with pT2 or higher stage of UUT-UC. CONCLUSIONS: Approximately 5% of the patients developed MIBC after nephroureterectomy with a median interval of 17 months. Patients with advanced pathologic stage (≥pT3) and a ureteral tumor location are at increased risk of developing MIBC after nephroureterectomy.
Kwang Hyun Kim; Dalsan You; In Gab Jeong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Related Documents :
22363115 - Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challe...
22760255 - A case of successful preoperative chemotherapy with cisplatin and irinotecan followed b...
22341295 - Quality of lymphadenectomy is equivalent with robotic and open cystectomy using an exte...
22664945 - Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in s...
11694775 - Adjuvant radio-chemotherapy in stage ii-iii rectal cancer with 24-hour infusion of high...
20226735 - Pet-ct for response assessment and treatment adaptation in head and neck cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-14
Journal Detail:
Title:  Urologic oncology     Volume:  -     ISSN:  1873-2496     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9805460     Medline TA:  Urol Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Department of Urology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Calix[4]arene derivative bearing imidazole groups as carrier for the transport of palladium by using...
Next Document:  Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extra...